Article info
Original research
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial
- Correspondence to Dr Maria Carmela Piccirillo, Unità Sperimentazioni Cliniche, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, 80131NA, Italy; m.piccirillo{at}istitutotumori.na.it
Citation
Thromboembolic events and antithrombotic prophylaxis in advanced ovarian cancer patients treated with bevacizumab: secondary analysis of the phase IV MITO-16A/MaNGO-OV2A trial
Publication history
- Received May 17, 2021
- Accepted August 16, 2021
- First published August 30, 2021.
Online issue publication
October 04, 2021
Article Versions
- Previous version (30 August 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.